CORT vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

CORT

43.6
AI Score
VS
CORT Wins

MRNA

42.9
AI Score

Investment Advisor Scores

CORT

44score
Recommendation
HOLD

MRNA

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CORT MRNA Winner
Revenue 421.05M 534.00M MRNA
Net Income 11.23M -2.13B CORT
Net Margin 2.7% -397.9% CORT
Operating Income -8.30M -2.20B CORT
ROE 1.6% -31.4% CORT
ROA 1.3% -19.4% CORT
Total Assets 888.70M 10.96B MRNA
Cash 111.04M 1.72B MRNA
Current Ratio 2.86 2.29 CORT
Free Cash Flow 14.04M -1.25B CORT

Relative Price Performance (Last 90 Days)

CORT 1M: +26.5% · 3M: +104.8% MRNA 1M: +154.5% · 3M: +207.1%

Current Technical Phase

CORT

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (22.8% over 20 days), RSI 71

RSI (14): 71.1 · Price: $122.25

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.2% over 20 days), RSI 72

RSI (14): 71.6 · Price: $145.13

Fundamentals Snapshot

Metric CORT MRNA
Market Cap
Forward P/E 27.8 -29.8
Trailing P/E 263.2
Revenue (TTM)
Revenue Growth 0.3% 0.0%
Gross Margin 1.0% -0.7%
Operating Margin 0.2% -5.6%
EPS 0.46 -6.11
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CORT is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.